Recombinant DNA Advisory Committee - 
Others: 
J.C. Alexander 
John A. Barranger, University of Pittsburgh 
M. Janies Barrett, Genetic Therapy, Inc. 
John Barry 
John Barton, Stanford Law School 
Arindam Bose, Pfizer Central Research 
Malcolm K. Brenner, St. Jude Children's Research Hospital 
Nancy Buc, Weil, Gotshal & Manges 
Yawen Chiang, Genetic Therapy, Inc. 
Thomas L. Copmann, Pharmaceutical Manufacturers Assoc. 
Van DeSilva 
Roy Doi, University of California, Davis 
Jerome Donlon, Food and Drug Administration 
Chris Evans, University of Pittsburgh 
Carol Ezzell, BioWorld 
Gershon W. Fishbein, Genetic Engineering Letter 
Diane O. Fleming, Merck & Co., Inc. 
Joseph R. Fordham, Nova Nordisk Bioindustrials, Inc. 
Joe Glorioso, University of Pittsburgh 
Robert Goldberg, Merck & Co., Inc. 
Alan R. Goldhammer, Industrial Biotechnology Association 
Venkat Gopal, Otsuka America Pharmaceuticals, Inc. 
Keith Haglund, Medical Tribune 
Lowell Harmison 
Eric Hoffman, University of Pittsburgh 
Patricia Hughes, Otsuka America Pharmaceuticals, Inc. 
James Ihle, St. Jude Children's Research Hospital 
Yasuo Iriye, Otsuka America Pharmaceuticals, Inc. 
Mitsuo Itakura, Tokushima University of Japan 
John E. Jaugstetter, Genentech, Inc. 
Roger D. Jennings, British Embassy 
Dorothy S. Jessop, Department of Agriculture 
Attila T. Kadar, Food and Drug Administration 
Daniel Kuebbing, Genetic Therapy, Inc. 
Morris Levin, Maryland Biotechnology Institute 
Michael T. Lotze, University of Pittsburgh 
Joseph Palca, Science Magazine 
Chris Plein, University of Missouri 
Fran Pollner, Medical World News 
Margaret McLaughlin, Office of Technology Assessment 
[448] 
Recombinant DNA Research, Volume 14 
